IMO Precision Literature Review, the newest solution from IMO Health, enables life sciences teams to complete systematic literature reviews (SLRs) faster by combining provider-native clinical terminology with advanced GenAI capabilities and human-in-the-loop oversight.
Regulatory submissions, health technology assessment (HTA) dossiers, and market access depend on timely, reliable reviews. Yet traditional approaches – often hindered by slow, outdated, and error-prone workflows – can take 6–18 months, while the volume of published literature doubles every 3–5 years. This leads to delayed filings, irreproducible evidence, and missed opportunities for innovation. IMO Precision Literature Review offers a solution with a platform designed for speed, specificity, and traceability.
Key capabilities include:
- End-to-end SLR workflow: From protocol design and search to screening, extraction, summarization, and reporting, this tool is adaptable to client-specific document sources and workflows
- Expert-level accuracy for AI automation: Validated through peer-reviewed pharma studies across epidemiology, clinical outcomes, and economic burden
- Human-in-the-loop transparency: Accelerating article triage and data extraction while ensuring transparency and auditability
- Clinical-grade normalization: Aligning outcomes and clinical nuance across studies using IMO Health’s terminology backbone
“Evidence generation is under immense pressure from rapidly expanding data volumes, complex trial designs, and rising regulatory expectations,” said Matt McKinley, General Manager of Life Sciences at IMO Health. “We’re seeing real breakthroughs where clinical precision meets scalable technology. IMO Precision Literature Review demonstrates how our clinical expertise can unlock the full value of scientific literature, delivering insights pharma can trust and defend.”
Evidence generation is under immense pressure from rapidly expanding data volumes, complex trial designs, and rising regulatory expectations. We're seeing real breakthroughs where clinical precision meets scalable technology. IMO Precision Literature Review demonstrates how our clinical expertise can unlock the full value of scientific literature, delivering insights pharma can trust and defend.
With IMO Precision Literature Review, pharma teams can cut review timelines from months to weeks and days, reduce analyst workload, and produce publication-ready evidence that stands up to scrutiny. In one recent case, a top-10 global pharma company used the solution to execute a vaccine cost-effectiveness review, replacing one full reviewer in the process and capturing critical data elements missed by humans, attaining both measurable efficiency gains and superior accuracy.
As life sciences organizations face mounting pressure to deliver timely, reproducible evidence, IMO Precision Literature Review stands as a cornerstone of IMO Health’s expanding life sciences portfolio – complementing solutions for trial enablement, cohorting, and real-world data normalization.
